Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.

Company Overview and News

Report: Putrajaya to approve Penang LRT project by year-end

2018-08-11 malaymail
KUALA LUMPUR, Aug 11 — Putrajaya will approve Penang’s proposed RM8.4 billion Bayan Lepas light rail transit (LRT) and Penang South Reclamation (PSR) scheme by the end of the year.

F&N, Omesti, Toyo Ink, Kronologi Asia, Scomi Group and Unisem

2018-08-02 theedgemarkets
KUALA LUMPUR (Aug 2): Based on corporate announcements and news flow today, companies in focus on Friday (Aug 3) may include: Fraser & Neave Holdings Bhd (F&N), Omesti Bhd, Toyo Ink Group Bhd, Kronologi Asia Bhd, Scomi Group Bhd and Unisem (M) Bhd.
0176 7173 7366 7158 7045

Mumbai: Starvation of cash, Malaysian project manager among many other reasons why monorail did not succeed

The monorail services in the city are getting worse with it’s services remaining suspended from November last year. Services from Chembur to Wadala (phase 1) were suspended after two rakes caught fire in November last year. On the other hand, phase 2 (from Wadala-Jacob Circle) is yet to become operational. The 10.6-km has missed 15 deadlines. The Mumbai Metropolian Region Development Authority (MMRDA) also called for new tenders to take over from Scomi Engineering, the Malaysian supplier and the operator of the Monorail coaches.

India beckons, but business challenges aplenty

2018-06-20 theedgemarkets
WITH a market of 1.2 billion people and a growing middle class, it is hard for anyone to ignore the economic potential of India. Malaysian companies too have been looking at the country to expand their markets.
6888 7366 IDEA ICLQY AXXTF 5085 532822

Related Articles

REPH: Recro Pharma Analysis and Research Report

2018-08-20 - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

2018-08-20 - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

2018-08-20 - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="